Company Filing History:
Years Active: 2020
Title: The Innovations of Stephen I Bandak
Introduction
Stephen I Bandak is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of controlled-release formulations. His work is aimed at improving treatment options for patients suffering from various conditions, including Parkinson's disease.
Latest Patents
Stephen I Bandak holds a patent for a controlled-release composition containing tozadenant. This innovative formulation includes at least one cellulose ether and one or more pharmaceutically acceptable excipients. The composition is designed to ensure specific dissolution rates of tozadenant over time, which is crucial for effective treatment. The patent outlines that the tozadenant is present in an amount ranging from about 30% (w/w) to about 65% (w/w) based on the total composition weight. The cellulose ether is included in a quantity sufficient to achieve not less than about 10% tozadenant dissolution over a 2-hour test period, not less than about 55% dissolution over a 10-hour test period, and not less than about 80% dissolution over a 16-hour test period. This formulation is particularly aimed at enhancing the treatment of Parkinson's disease.
Career Highlights
Stephen I Bandak is associated with Biotie Therapies Corporation, where he continues to innovate in the pharmaceutical sector. His work has been instrumental in advancing drug delivery systems that improve patient outcomes. With a focus on controlled-release technologies, Bandak's contributions are paving the way for more effective therapies.
Collaborations
Stephen has collaborated with notable colleagues such as Thomas R Malefyt and Christopher G Salentine. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Stephen I Bandak's work exemplifies the impact of innovative thinking in the pharmaceutical industry. His patent for controlled-release tozadenant formulations represents a significant advancement in treatment options for Parkinson's disease. Through his career at Biotie Therapies Corporation, Bandak continues to contribute to the field, making strides that benefit patients and the medical community alike.